Drug Profile
Research programme: neurological disorder therapeutics - SYGNIS Pharma
Alternative Names: AX 300; CNS programme - SYGNIS Pharma; Neuroregeneration programme - SYGNIS Pharma; Neurotherapy programme - SYGNIS Pharma; SY 300Latest Information Update: 30 Jul 2012
Price :
$50
*
At a glance
- Originator SYGNIS Pharma
- Class Neuroprotectants; Small molecules
- Mechanism of Action Apoptosis inhibitors; Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 25 Jul 2012 Discontinued for Neurological disorders in Germany (unspecified route)
- 26 Jul 2007 Early research in Neurological disorders in Germany (unspecified route)